<code id='177168C47E'></code><style id='177168C47E'></style>
    • <acronym id='177168C47E'></acronym>
      <center id='177168C47E'><center id='177168C47E'><tfoot id='177168C47E'></tfoot></center><abbr id='177168C47E'><dir id='177168C47E'><tfoot id='177168C47E'></tfoot><noframes id='177168C47E'>

    • <optgroup id='177168C47E'><strike id='177168C47E'><sup id='177168C47E'></sup></strike><code id='177168C47E'></code></optgroup>
        1. <b id='177168C47E'><label id='177168C47E'><select id='177168C47E'><dt id='177168C47E'><span id='177168C47E'></span></dt></select></label></b><u id='177168C47E'></u>
          <i id='177168C47E'><strike id='177168C47E'><tt id='177168C47E'><pre id='177168C47E'></pre></tt></strike></i>

          Home / Wikipedia / explore

          explore


          explore

          author:explore    Page View:251
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In